Stress-Dose Glucocorticoid Therapy for CIRCI
For patients with septic shock unresponsive to fluid resuscitation and moderate-to-high-dose vasopressors, administer intravenous hydrocortisone less than 400 mg/day (typically 200 mg/day) for at least 3 days at full dose. 1
Clinical Context and Pathophysiology
CIRCI represents dysregulated systemic inflammation from inadequate intracellular glucocorticoid-mediated anti-inflammatory activity relative to illness severity. This manifests as hypotension refractory to fluids, decreased catecholamine sensitivity, and persistent shock despite adequate resuscitation 1.
Condition-Specific Recommendations
Septic Shock (Primary Indication)
- Agent: IV hydrocortisone
- Dose: <400 mg/day (commonly 200 mg/day divided or continuous infusion at 10 mg/hr)
- Duration: ≥3 days at full dose
- Indication: Shock not responsive to fluid resuscitation AND moderate-to-high-dose vasopressor therapy
- Evidence quality: Conditional recommendation, low quality evidence 1
Critical distinction: Do NOT use corticosteroids in sepsis without shock (conditional recommendation, moderate quality evidence) 1.
Acute Respiratory Distress Syndrome
- Agent: IV methylprednisolone
- Dose: 1 mg/kg/day
- Timing: Early moderate-to-severe ARDS (PaO2/FiO2 <200 within 14 days of onset)
- Evidence quality: Conditional recommendation, moderate quality evidence 1
Major Trauma
- Recommendation: Corticosteroids NOT suggested (conditional, low quality evidence) 1
Diagnostic Approach
While no single test reliably diagnoses CIRCI, clinicians may use 1:
- Delta cortisol: <9 μg/dL increase at 60 minutes after cosyntropin 250 μg administration
- Random plasma cortisol: <10 μg/dL
Important caveat: The 2017 SCCM/ESICM guidelines explicitly state the task force could NOT reach agreement on a single reliable diagnostic test. Treatment decisions should be based on clinical presentation (refractory shock) rather than waiting for test results 1.
Administration Strategy
Hydrocortisone dosing options 2:
- 200 mg/day as continuous IV infusion (preferred for steady levels)
- 50 mg IV every 6 hours (alternative)
- 100 mg IV every 8 hours (alternative)
Duration and tapering:
- Maintain full dose for minimum 3 days 1
- Taper gradually rather than abrupt discontinuation
- Consider reinstitution if shock recurs during taper
Clinical Pitfalls
Don't use dexamethasone for CIRCI treatment—it lacks mineralocorticoid activity needed in septic shock 3
Avoid high doses: Doses ≥400 mg/day hydrocortisone equivalent show no additional benefit and may increase adverse effects 1
Don't delay treatment for diagnostic testing in refractory shock—initiate empirically if CIRCI suspected 2
Monitor for hyperglycemia: Most common adverse effect requiring management 4
Recognize clinical signs: Hypotension refractory to fluids, decreased vasopressor response, hyponatremia, hyperkalemia, hypoglycemia 1
Evidence Strength and Nuances
The 2017 SCCM/ESICM guidelines used GRADE methodology with 80% task force agreement threshold 1. The recommendations are conditional (not strong) because:
- Quality of evidence ranges from low to moderate
- Benefits are modest (shock reversal, reduced vasopressor duration) rather than dramatic mortality reduction
- Individual patient response varies
Recent meta-analyses suggest early initiation (≤72 hours), low-dose, and prolonged therapy (≥7 days) may optimize outcomes in severe pneumonia and ARDS 4. For septic shock specifically, combination therapy with fludrocortisone may enhance efficacy, though this requires further validation 4.
The evidence does NOT support routine use in all critically ill patients—only those meeting specific criteria for septic shock or early severe ARDS 1, 5.